In this episode of the PPTI Podcast, Thijs Bosch, recently appointed CEO of The Protein Brewery, discusses the company’s milestone €30 million Series B funding round and its vision for the future of fungi-based proteins. He explains how his background in specialty proteins and scale-up ventures is helping drive commercialization and global expansion.
Thijs highlights the unique advantages of The Protein Brewery’s proprietary fungal strain, which enables efficient, lower-capex fermentation under non-sterile conditions – making scaling and partnerships more attainable. He shares progress from pilot to demonstration-scale production, details on regulatory pathways in the USA, Singapore, and Europe, and the importance of building both technical and commercial capabilities to support growth.
The conversation explores how the company’s ingredient delivers complete protein, fiber, and micronutrients in a neutral-tasting, odorless form suited for a wide range of applications. Thijs emphasizes that long-term success will depend on disciplined scaling, smart market entry, and balancing investor expectations with lasting impact across sustainable food systems.